After speaking with MEDACorp nephrologists and conducting an analysis of recent data on the first two patients with C3 glomerulopathy treated with Achillion's ACH-4471, Leerink analyst Joseph Schwartz has an "enhanced appreciation" of the early signal of decreased proteinuria and market opportunity for it in C3G. The analyst believes '4471 is converging on modified partial remissions, which the FDA has stated may be used as a primary endpoint in other orphan kidney diseases. Schwartz is looking forward to data updates in 2018 on higher doses, longer duration of therapy, and more patients. He reiterates an Outperform rating and $5 price target on the shares.